| Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer J Heo, T Reid, L Ruo, CJ Breitbach, S Rose, M Bloomston, M Cho, HY Lim, ... Nature medicine 19 (3), 329-336, 2013 | 839 | 2013 |
| Going viral with cancer immunotherapy BD Lichty, CJ Breitbach, DF Stojdl, JC Bell Nature Reviews Cancer 14 (8), 559-567, 2014 | 660 | 2014 |
| Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans CJ Breitbach, J Burke, D Jonker, J Stephenson, AR Haas, LQM Chow, ... Nature 477 (7362), 99-102, 2011 | 625 | 2011 |
| Translational control of the innate immune response through IRF-7 R Colina, M Costa-Mattioli, RJO Dowling, M Jaramillo, LH Tai, ... Nature 452 (7185), 323-328, 2008 | 370 | 2008 |
| Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow CJ Breitbach, JM Paterson, CG Lemay, TJ Falls, A McGuire, KA Parato, ... Molecular Therapy 15 (9), 1686-1693, 2007 | 367 | 2007 |
| The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers KA Parato, CJ Breitbach, F Le Boeuf, J Wang, C Storbeck, C Ilkow, ... Molecular Therapy 20 (4), 749-758, 2012 | 325 | 2012 |
| Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans CJ Breitbach, R Arulanandam, N De Silva, SH Thorne, R Patt, ... Cancer research 73 (4), 1265-1275, 2013 | 276 | 2013 |
| Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells LH Tai, CT De Souza, S Bélanger, L Ly, AA Alkayyal, J Zhang, JL Rintoul, ... Cancer research 73 (1), 97-107, 2013 | 225 | 2013 |
| Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis TLA Nguyên, H Abdelbary, M Arguello, C Breitbach, S Leveille, JS Diallo, ... Proceedings of the National Academy of Sciences 105 (39), 14981-14986, 2008 | 219 | 2008 |
| Targeting tumor vasculature with an oncolytic virus CJ Breitbach, NS De Silva, TJ Falls, U Aladl, L Evgin, J Paterson, YY Sun, ... Molecular Therapy 19 (5), 886-894, 2011 | 210 | 2011 |
| Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer SH Park, CJ Breitbach, J Lee, JO Park, HY Lim, WK Kang, A Moon, ... Molecular Therapy 23 (9), 1532-1540, 2015 | 185 | 2015 |
| A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma TH Hwang, A Moon, J Burke, A Ribas, J Stephenson, CJ Breitbach, ... Molecular Therapy 19 (10), 1913-1922, 2011 | 178 | 2011 |
| Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients TP Cripe, MC Ngo, JI Geller, CU Louis, MA Currier, JM Racadio, ... Molecular Therapy 23 (3), 602-608, 2015 | 175 | 2015 |
| First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity HJ Zeh, S Downs-Canner, JA McCart, ZS Guo, UNM Rao, L Ramalingam, ... Molecular Therapy 23 (1), 202-214, 2015 | 172 | 2015 |
| Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy J Heo, CJ Breitbach, A Moon, CW Kim, R Patt, MK Kim, YK Lee, SY Oh, ... Molecular Therapy 19 (6), 1170-1179, 2011 | 160 | 2011 |
| Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers S Downs-Canner, ZS Guo, R Ravindranathan, CJ Breitbach, ME O'malley, ... Molecular Therapy 24 (8), 1492-1501, 2016 | 141 | 2016 |
| Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans MK Kim, CJ Breitbach, A Moon, J Heo, YK Lee, M Cho, JW Lee, SG Kim, ... Science translational medicine 5 (185), 185ra63-185ra63, 2013 | 118 | 2013 |
| Oncolytic viruses: therapeutics with an identity crisis CJ Breitbach, BD Lichty, JC Bell EBioMedicine 9, 31-36, 2016 | 116 | 2016 |
| Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma XQ Lun, J Chan, H Zhou, B Sun, JJP Kelly, OO Stechishin, JC Bell, ... Molecular Therapy 18 (11), 1927-1936, 2010 | 114 | 2010 |
| VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection R Arulanandam, C Batenchuk, FA Angarita, K Ottolino-Perry, ... Cancer Cell 28 (2), 210-224, 2015 | 108 | 2015 |
